Oral anticoagulant prescribing among patients with cancer and atrial fibrillation in England, 2009-2019.
Alyaa M AjabnoorRosa ParisiSalwa S ZghebiDarren M AshcroftCorinne Faivre-FinnCharlotte MorrisMamas A MamasEvangelos KontopantelisPublished in: Cancer (2023)
In patients with AF, underprescribing of OAC is independently associated with certain cancer types. Patients with hematological and lung cancer are the least likely to receive anticoagulation therapy compared with patients without cancer. Underprescribing of OAC in cancer is linked to old age. Further studies of patients with AF and cancer are warranted to assess the net clinical benefit of anticoagulation in certain cancer types.
Keyphrases
- atrial fibrillation
- papillary thyroid
- squamous cell
- primary care
- venous thromboembolism
- heart failure
- emergency department
- lymph node metastasis
- ejection fraction
- coronary artery disease
- newly diagnosed
- young adults
- chronic kidney disease
- mesenchymal stem cells
- oral anticoagulants
- direct oral anticoagulants
- smoking cessation
- prognostic factors
- left ventricular
- replacement therapy